Why the study?
Does dopamine improve hemodynamic and clinical responses compared to isoproterenol in patients with shock syndrome?
Does dopamine improve hemodynamic and clinical responses compared to isoproterenol in patients with shock syndrome?
Optimal sympathomimetic amine therapy in shock requires individualized selection of dopamine or isoproterenol based on the patient's underlying hemodynamic status.
Individualized dopamine or isoproterenol selection by resistance status may optimize shock response; leaves open randomized confirmation.
The hemodynamic responses to isoproterenol and dopamine were investigated in 22 patients with the shock syndrome from various etiologies. Dopamine was superior to isoproterenol in seven patients with normal or low peripheral resistance. In this group of patients administration of isoproterenol was associated with unacceptably low blood pressure. Isoproterenol was superior in three patients in whom dopamine did not increase cardiac output. Both amines produced adequate clinical response in four patients, and a combination of isoproterenol and dopamine was necessary for adequate therapy in two patients. Six patients did not respond hemodynamically or clinically to either dopamine or isoproterenol. This investigation has demonstrated that optimal sympathomimetic amine therapy of shock is facilitated by an analysis of hemodynamic status and responses to drug administration.
No takes yet. Share an insight, caveat, or question.
Talley et al. (1969) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: